ArticleJournal of biochemical and molecular toxicology2026
Protective Effect and Mechanism of Rosiglitazone in α-amanitin-induced Hepatotoxicity Via Activation of PPAR-γ/Nrf2 Signaling Pathway.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective Effect and Mechanism of Rosiglitazone in α-amanitin-induced Hepatotoxicity Via Activation of PPAR-γ/Nrf2 Signaling Pathway.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
α-amanitin (α-AMA), the primary lethal toxin of amanita, primarily targets the liver with a high toxicity and a low lethal dose. As the precise mechanism of intoxication is unclear, and specific antidotes are lacking, α-AMA-induced liver injury has a high mortality rate. As a selective PPAR-γ agonist, Rosiglitazone (RSG) alleviates liver injury by upregulating the PPAR-γ/Nrf2 signaling pathway, thereby enhancing antioxidant effects, mitigating inflammation, and reducing apoptosis. This study investigated the protective role and mechanism of action of RSG in α-AMA-induced acute liver injury in ICR mice. We established an experimental model and examined hepatic injury markers, focusing on PPAR-γ/Nrf2 pathway activation. Overall, α-AMA intoxication led to dose-dependent increases in serum ALT/AST levels, accompanied by hepatocellular necrosis. This was associated with the onset of oxidative stress, characterized by the accumulation of malondialdehyde (MDA), excessive ROS production, and reduced activities of the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT). Furthermore, we observed the upregulation of pro-inflammatory mediators (TNF-α, IL-6, and IL-8), suppression of the PPAR-γ/Nrf2 cytoprotective axis, and hepatocyte apoptosis induced via activation of the P53/caspase-3 pathway, ultimately resulting in murine mortality. RSG treatment alleviated oxidative stress and the inflammatory response, reduced hepatocellular necrosis and apoptosis, and improved survival rates in α-AMA-intoxicated mice by upregulating the PPAR-γ/Nrf2 signaling pathway in hepatocytes. Early RSG intervention can thereby effectively mitigate α-AMA-induced acute liver injury by upregulating the PPAR-γ/Nrf2 signaling pathway. Future studies should focus on exploring the clinical potential of RSG as a therapeutic agent for amanita mushroom poisoning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.